REG - Aptamer Group PLC - Optimer® Technology in Launched Library Prep Kit

AptamerAnnouncement

11/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260211:nRSK5060Sa&default-theme=true

RNS Number : 5060S  Aptamer Group PLC  11 February 2026

 

11 February 2026

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Optimer® Technology in Newly Launched Library Prep Kit

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, is pleased to announce that Twist
Bioscience Corporation has launched its new TrueAmp Library Preparation Kit,
which uses Aptamer's proprietary Optimer® binders as an enabling technology
for stability at room temperature, within the TrueAmp Library Preparation
Kit¹.

 

Product Launch

The TrueAmp Library Preparation Kit represents a significant advancement in
next-generation sequencing (NGS) library amplification workflows. By using
Aptamer's Optimer® binders, the Twist TrueAmp Library Prep Kit delivers a new
level of exceptional performance to Twist's library preparation portfolio.
These advantages are enabled by Twist's in-house developed enzymes, including
a previously developed ligase and a newly developed polymerase.

 

Engineered for NGS applications, the specialised TrueAmp polymerase maximises
coverage across typically hard-to-sequence regions of the genome - while
maintaining high accuracy during DNA copying. The kit delivers high yields
even from low-input or degraded starting samples, which minimises
amplification-introduced errors and results in more usable high-quality data.
To streamline large-scale workflows, the Twist TrueAmp Library Prep Kit has
been validated with the Twist HT-UDI adapter system, allowing for up to 3,072
unique indexes as well as Twist UMI adapters, ensuring precise strand
identification and efficient multiplexing.

 

Partnership Background

As announced in December 2025,(2) Aptamer issued a non-exclusive license to
Twist Bioscience for the use of the Optimer inhibitor for a proprietary
high-fidelity polymerase.

 

This partnership strategically combines Twist Bioscience's expertise in
synthetic biology and genomics with Aptamer's pioneering Optimer® binder
technology to create solutions for the rapidly expanding next-generation
sequencing market.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are
delighted to play a small but significant part in Twist Bioscience bringing
the TrueAmp Library Preparation Kit to market. This product launch
demonstrates the real-world value of our Optimer® technology in enabling
market-ready products.

 

In this hot-start PCR application, the Optimer® binder demonstrates robust
performance, eliminating the need for two separate antibody reagents typically
required in alternative methods. We look forward to the continued success of
our collaboration with Twist Bioscience and the transformative impact this
product will have in advancing genomics research and clinical applications."

 

1.    TrueAmp Library Preparation Kit
(https://www.twistbioscience.com/next-generation-sequencing/library-preparation-solutions/trueamp-library-prep-kit/)

1.    Twist Bioscience Launches Next Generation Library Preparation Kits
Powered by Proprietary Enzymes
(https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-launches-next-generation-library-preparation)

2.    Aptamer signs licensing agreement with Twist Bioscience
(https://polaris.brighterir.com/public/aptamer_group/news/rns/story/wk4362r)

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott  
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 Andrew Thacker / Guy McDougall
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders for
the life sciences industry. The Group develops Optimer® binders, advanced
molecules that act like antibodies by binding to specific targets. These
binders are used in medicine, diagnostic tests, and research tools, offering
benefits such as high stability, reliable performance, and lower costs
compared with traditional antibodies.

 

Aptamer operates a fee‑for‑service business in the global market for
antibody alternatives, working with leading pharmaceutical and life‑science
companies, including all of the top 10 global pharmaceutical companies. It is
also building a portfolio of Optimer® assets with partners, aiming to
generate future licensing and royalty revenues.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLDXGDDSSBDGLG



            Copyright 2019 Regulatory News Service, all rights reserved